FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors. Fallah J, Brave MH, Weinstock C, Mehta GU, et al. Clin Cancer Res 2022;28:4843-4848.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Fallah J, Brave MH, Weinstock C, Mehta GU, et al. FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors. Clin Cancer Res 2022;28:4843-4848.
PMID: 35727604